1. "Andrew Zelenetz"
Formats
  1. Meeting Abstract (418)
  2. Journal Article (273)
  3. Research Letter (9)
  4. Book Section (7)
  5. Conference Paper (3)
  6. Editorial (3)
  7. Guidelines (3)
  8. Correspondence (1)
  9. Review (1)
Groups
  1. Center for Hematologic Malignancies (718)
  2. Department of Medicine (718)
  3. Hematologic Malignancies, Division of (718)
  4. Lymphoma (718)
  5. Survivorship Research (212)
  6. Population Sciences Research Program (159)

More Groups

People
  1. Andrew Zelenetz (718)
  2. Craig Moskowitz (206)
  3. David Straus (155)
  4. Ariela Noy (153)
  5. Paul Hamlin (148)
  6. Steven Horwitz (141)

More People

Years
  1. 2023 (15)
  2. 2022 (30)
  3. 2021 (29)
  4. 2020 (32)
  5. 2019 (39)
  6. 2018 (15)

More Years

Publications
  1. Blood (287)
  2. Journal of Clinical Oncology (82)
  3. Journal of the National Comprehensive Cancer Network (34)
  4. British Journal of Haematology (30)
  5. Leukemia and Lymphoma (27)
  6. Annals of Oncology (26)

More Publications

Publishers
  1. American Society of Hematology (296)
  2. American Society of Clinical Oncology (84)
  3. John Wiley & Sons (37)
  4. Harborside Press (34)
  5. Oxford University Press (31)
  6. Elsevier Inc. (29)

More Publishers

Results (718)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment
    Meeting Abstract

    Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I. W.; Alencar, A. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma
    Journal Article

    Wang, M. L.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; Flinn, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy
    Editorial

    Luttwak, E.; Smith, M. R.; Zelenetz, A. D.
    Expert Opinion on Pharmacotherapy (2023)

    Fulltext@MSK | Save
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A.; Salles, G.; Yahalom, J.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent BTK‐inhibitor pre‐treated mantle cell lymphoma: Updated results, subgroup analysis from bruin with >3 years follow‐up from start of enrollment
    Meeting Abstract

    Cheah, C. Y.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; Alencar, A. J.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of (18)F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen
    Journal Article

    Michaud, L.; Bantilan, K.; Mauguen, A.; Moskowitz, C. H.; Zelenetz, A. D.; Schöder, H.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save